Enter your keyword

Efficiently Creating Value with Innovative Science

Investors & News

Investor Overview
Press Releases
Stock Quote
SEC Filings
Events & Presentations
Investor Contacts
Alerts
Corporate Governance

Day High:
Day Low:
Volume:

8:16 AM EDT May 25, 2019

Copyright West LLC. Minimum 15 minutes delayed.

Intra
3 mo.
6 mo.
1 yr.

Unsubscribe from all Mateon Therapeutics email alerts

Email Address

Shareholder Tools

Email Alerts

Email Alerts
Downloads

Downloads
Print

Print
Share

Share
Search

Search

Facebook
Google
LinkedIn
Twitter
RSS

About Mateon

Mateon Therapeutics is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These 2 approaches (VDAs and AAs) have distinct yet complementary mechanisms of action. At Mateon, we believe that we can significantly improve cancer therapy by combining these 2 complementary approaches.

Links

Home
Our Company
Our Science
Product Development
Investors & News
Careers
Contact Us

Our Office

Mateon Corporate Headquarters

701 Gateway Blvd, Suite 210
South San Francisco, CA 94080
info@mateon.com
(650) 635-7000
(650) 635-7001